Institute Biofunctional Polymer Materials, Max Bergmann Center of Biomaterials, Leibniz-Institut für Polymerforschung Dresden e.V., Dresden, Germany; Key Laboratory of Advanced Technology for Materials of Education Ministry, School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
i3S, Instituto de Investigação e Inovação em Saúde, Portugal; INEB, Instituto de Engenharia Biomédica, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal; ICBAS, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.
Acta Biomater. 2019 Aug;94:33-43. doi: 10.1016/j.actbio.2019.06.019. Epub 2019 Jun 19.
Biomedical devices in the blood flow disturb the fine-tuned balance of pro- and anti-coagulant factors in blood and vessel wall. Numerous technologies have been suggested to reduce coagulant and inflammatory responses of the body towards the device material, ranging from camouflage effects to permanent activity and further to a responsive interaction with the host systems. However, not all types of modification are suitable for all types of medical products. This review has a focus on application-oriented considerations of hemocompatible surface fittings. Thus, passive versus bioactive modifications are discussed along with the control of protein adsorption, stability of the immobilization, and the type of bioactive substance, biological or synthetic. Further considerations are related to the target system, whether enzymes or cells should be addressed in arterial or venous system, or whether the blood vessel wall is addressed. Recent developments like feedback controlled or self-renewing systems for drug release or addressing cellular regulation pathways of blood platelets and endothelial cells are paradigms for a generation of blood contacting devices, which are hemocompatible by cooperation with the host system. STATEMENT OF SIGNIFICANCE: This paper is part 4 of a series of 4 reviews discussing the problem of biomaterial associated thrombogenicity. The objective was to highlight features of broad agreement and provide commentary on those aspects of the problem that were subject to dispute. We hope that future investigators will update these reviews as new scholarship resolves the uncertainties of today.
生物医学设备在血流中会破坏血液和血管壁中促凝和抗凝因子之间的精细平衡。已经提出了许多技术来减少机体对器械材料的凝血和炎症反应,范围从伪装效应到永久活性,再到与宿主系统的响应性相互作用。然而,并非所有类型的修饰都适用于所有类型的医疗产品。本综述重点关注对血液相容性表面贴合的应用导向考虑。因此,讨论了被动与生物活性修饰,以及蛋白质吸附的控制、固定化的稳定性以及生物或合成的生物活性物质的类型。进一步的考虑与目标系统有关,是在动脉或静脉系统中处理酶还是细胞,还是处理血管壁。最近的发展,如用于药物释放的反馈控制或自我更新系统,或针对血小板和内皮细胞的细胞调节途径,都是与宿主系统合作实现血液相容性的新一代接触血液的设备的范例。
本文是讨论生物材料相关血栓形成问题的 4 篇综述系列的第 4 部分。目的是突出广泛共识的特征,并就该问题存在争议的方面提供评论。我们希望未来的研究人员将随着新的学术研究解决今天的不确定性来更新这些综述。